COMBIHALE FB 200 RESPICAPS

Description

COMBIHALE FB 200 RESPICAPS contain a fixed-dose combination of Formoterol Fumarate (200 mcg), a long-acting beta-2 agonist (LABA), and Budesonide (400 mcg), an inhaled corticosteroid (ICS). This combination provides both bronchodilation and anti-inflammatory effects, making it effective for the long-term management of asthma and chronic obstructive pulmonary disease (COPD).

Formoterol relaxes airway muscles to improve airflow, while Budesonide reduces airway inflammation, helping to prevent asthma attacks and exacerbations of COPD. The RESPICAPS are designed for use with a dry powder inhaler device, ensuring precise delivery of medication to the lungs.

Key Benefits:

• Dual-action inhalation therapy for better symptom control

• Reduces airway inflammation and bronchoconstriction

• Helps prevent asthma attacks and COPD exacerbations

• Convenient capsule form for inhalation via dry powder inhaler

Indications:

• Asthma maintenance therapy

• Chronic Obstructive Pulmonary Disease (COPD) management

Dosage:
As prescribed by the physician, typically inhaling the contents of one capsule twice daily using the inhaler device.

Precautions:
Not for acute asthma attacks. Use under medical supervision. Monitor for side effects like tremors, headache, or oral thrush.